Key result
Renal denervation shows promise as an antiarrhythmic therapy for AF with comorbid resistant hypertension.
Why the study?
Does renal denervation improve or prevent atrial fibrillation in patients with resistant arterial hypertension?
Does renal denervation improve or prevent atrial fibrillation in patients with resistant arterial hypertension?
The paper proposes investigating renal denervation as a potential antiarrhythmic therapy for atrial fibrillation, given its established role in treating resistant arterial hypertension.
Renal denervation warrants prospective RCTs in hypertensive AF; leaves open whether antiarrhythmic effects exist independent of BP lowering.
The autonomous nervous system plays a key role in modulation of cardiac electrophysiology. Despite a great body of data on the presence of anatomic and functional relations between the nervous system and the heart, there remain a number of questions unanswered. Denervation of renal arteries or renal denervation (RDN) has become a crucial interventional technique when treating resistant arterial hypertension (AHT). Since the latter is the most prevailing cardiovascular disease complicating the course of heart rhythm disorders, atrial fibrillations in particular, it would be a good idea to study a potential value of RDN as antiarrhythmic therapy.
No takes yet. Share an insight, caveat, or question.
Romanov et al. (2015) conducted a review in Atrial fibrillation and resistant arterial hypertension. Renal denervation (RDN) was evaluated. Renal denervation is proposed as a potential antiarrhythmic therapy for atrial fibrillation, particularly given its established role in treating comorbid resistant arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: